Paradigms and controversies in the treatment of HIV-related Burkitt lymphoma

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Burkitt lymphoma (BL) is a very aggressive subtype of non-Hodgkins lymphoma that occurs with higher frequency in patients with HIV/AIDS. Patients with HIV-related BL (HIV-BL) are usually treated with high-intensity, multi-agent chemotherapy regimens. The addition of the monoclonal antibody Rituximab to chemotherapy has also been studied in this setting. The potential risks and benefits of commonly used regimens are reviewed herein, along with a discussion of controversial issues in the practical management of HIV-BL, including concurrent anti-retroviral therapy, treatment of relapsed and/or refractory disease, and the role of stem cell transplantation.

Original languageEnglish
Article number403648
JournalAdvances in Hematology
StatePublished - 2012
Externally publishedYes


Dive into the research topics of 'Paradigms and controversies in the treatment of HIV-related Burkitt lymphoma'. Together they form a unique fingerprint.

Cite this